What Are GIP and GLP-1?
Incretin hormones play a vital role in regulating glucose after meals. Two of the most important are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are secreted in the gut in response to food, but their effects and mechanisms differ.
- GLP-1 boosts insulin secretion, inhibits glucagon, slows stomach emptying, and reduces appetite—making it a powerful target for weight loss and diabetes drugs.
- GIP also stimulates insulin release, but uniquely influences lipid metabolism and adipose tissue, potentially modulating how the body stores and mobilizes fat.
Why Combine GIP and GLP-1?
For years, medications like GLP-1 receptor agonists transformed diabetes and obesity care, but not all patients reach their goals on GLP-1 alone. Research uncovered that GIP, when co-activated with GLP-1, may unlock additional metabolic advantages:
- Enhanced insulin secretion during meals, even as insulin resistance rises.
- Lower risk of hypoglycemia compared to therapies that push insulin independently of glucose.
- Possible improvement in how the body handles fatty acids, reducing ectopic fat accumulation.
- Appetite suppression via complementary actions in the brain's satiety centers.
This rationale underpins the design of dual GIP/GLP-1 agonists like tirzepatide—a new era of treatment that goes beyond single-hormone targeting.
How Does Tirzepatide Work as a GIP/GLP-1 Agonist?
Tirzepatide is the first-in-class dual agonist approved for clinical use. It acts on both GIP and GLP-1 receptors, improving glucose control and appetite signals. The result, as shown in large clinical trials:
- HbA1c reduction: Up to 2.5% decrease from baseline in type 2 diabetes—greater than leading GLP-1 agents.
- Weight loss: Mean losses of 15–22% of starting body weight in obesity studies, with a higher percentage of patients achieving ≥15% loss.
- Cardiometabolic improvements: Lowered blood pressure, improved lipid profiles, and reduced markers of inflammation in many patients.
These results have sparked widespread interest among endocrinologists and primary care providers, especially for those managing patients with complex metabolic needs.
Comparing to GLP-1-Only Medications
Compared to well-known GLP-1 agonists like semaglutide (mounjaro is the commercial name for tirzepatide in the U.S.), tirzepatide has demonstrated:
- Greater average weight loss at matched doses.
- Slightly faster glycemic control improvements.
- A similar, not increased, risk of gastrointestinal side effects (nausea, vomiting, diarrhea), with some studies showing a lower discontinuation rate due to side effects.
The difference? By using dual incretin pathways, tirzepatide delivers on the promise of better metabolic control with tolerability comparable to single-hormone therapies. For patients who have plateaued or are not candidates for higher-dose GLP-1 drugs, GIP/GLP-1 dual agonism expands therapeutic options.
Related: Learn about tirzepatide dosage strategies and side effect management.
Who Should Consider GIP/GLP-1 Agonists?
Dual agonist therapy is most impactful for:
- Adults with type 2 diabetes not meeting A1c goals despite oral agents or single-agonist injectables.
- Individuals with obesity (BMI ≥30), or BMI ≥27 with comorbidities, who have struggled with lifestyle and previous pharmacotherapy.
- Patients needing both weight and glycemic control for cardiovascular risk reduction.
Prescribers typically follow a careful titration schedule to minimize GI symptoms. For more on safety, see our section on tirzepatide side effects.
Current Research and Future Directions
Ongoing studies are evaluating tirzepatide and next-generation GIP/GLP-1 agents for broader applications—such as non-alcoholic steatohepatitis (NASH), polycystic ovary syndrome (PCOS), and even Alzheimer’s prevention. Early biomarkers suggest benefits may extend beyond glucose and body weight. However, long-term cardiovascular outcome data are still being collected, so all use should be guided by up-to-date clinical evidence and shared decision-making.
For anyone considering medical weight loss with incretin therapies, it's essential to work closely with an experienced healthcare provider and to monitor for any adverse events.
Clinician’s Insight: In my experience managing patients with tirzepatide, those who respond best are engaged in ongoing lifestyle changes and close follow-up. The medication is a powerful tool, but coordinated care yields the most sustainable results.